Endotoxemia Clinical Trial
Official title:
The Effect of Ticagrelor on the Inflammatory Response to Human Endotoxemia
Rationale:
In patients suffering a myocardial infarction the P2Y12 receptor antagonists prasugrel and
ticagrelor improve outcome and prognosis compared to clopidogrel. Moreover, ticagrelor
lowers mortality from pulmonary infections and sepsis, which cannot solely be explained by
its platelet-inhibiting effect. An effect on the inflammatory response in the setting of
acute myocardial might underlie this phenomenon and if substantiated support a novel
beneficial mechanism of the new the P2Y12 receptor antagonists.
Objective:
To study whether ticagrelor, added to acetylsalicylic acid, modulates the inflammatory
response to the administration of lipopolysaccharide (LPS) in humans in vivo, and to compare
this effect with the P2Y12 antagonist clopidogrel.
Study design:
Prospective randomized placebo-controlled trial, according to a PROBE design (prospective
randomized open blinded-endpoint study).
Study population:
Forty healthy male volunteers aged ≥ 18 and ≤ 35 years. Intervention (if applicable):
Participants will be randomized to receive either placebo (twice daily), acetylsalicylic
acid (80 mg once daily, after a loading dose of 160 mg) + placebo (once daily),
acetylsalicylic acid (80 mg once daily, after a loading dose of 160 mg) + ticagrelor (90 mg
twice daily, after a loading dose of 180 mg) or acetylsalicylic acid (80 mg once daily,
after a loading dose of 160 mg)+ clopidogrel (75 mg once daily, after a loading dose of
300mg).
Main study parameters/endpoints:
Endpoints: area under the curve of the proinflammatory cytokines TNF-alpha, IL6, IL-10,
IL1ra IL-8, IL-1β, MCP-1 MIP-1a, MIP-1b en IFN; peak concentrations of the various
cytokines; plasma concentration of HMGP1; platelet-monocyte complex formation and markers of
platelet function; plasma concentration of adenosine.
Status | Completed |
Enrollment | 40 |
Est. completion date | December 2015 |
Est. primary completion date | December 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 35 Years |
Eligibility |
Inclusion Criteria: - Age = 18 and = 35 years - Male - No known current medical/psychiatric diseases Exclusion Criteria: - History, signs or symptoms of any cardiovascular disease - History of chronic obstructive pulmonary disease (COPD) or asthma - History of hemorrhagic diathesis, or any other disorder associated with increased risk of bleeding - Previous spontaneous vagal collapse - Use of any medication - Smoking - Liver enzyme abnormalities (defined as ALAT and/or ASAT > twice upper limit of normality) - Thrombocytopenia (<150*109 /ml) or anemia (haemoglobin < 8.0 mmol/L) - Any obvious disease associated with immune deficiency - Febrile illness in the week before the LPS challenge - Hypersensitivity to ticagrelor or any excipients - Active pathological bleeding - History of intracranial haemorrhage - History of dyspepsia - quantitative bleeding assessment tool (BAT) score >3 (see Appendix 1) - Participation in another drug trial or donation of blood 3 months prior, until 3 months after the planned LPS challenge - Cardiac conduction abnormalities on the ECG consisting of a 2nd degree atrioventricular block, third degree atrioventricular block or a complex bundle branch block - Hypertension (defined as RR systolic > 160 or RR diastolic > 90) - Hypotension (defined as RR systolic < 100 or RR diastolic < 50) - Renal impairment (defined as MDRD < 60 ml/min) |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science
Country | Name | City | State |
---|---|---|---|
Netherlands | Intensive Care Medicine, Radboud University Nijmegen Medical Centre | Nijmegen | Gelderland |
Lead Sponsor | Collaborator |
---|---|
Radboud University |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | concentration plasma TNFalpha (pg/ml) | measured with Luminex assay | measured after challenge with endotoxin at day 7 of medication | No |
Secondary | concentration plasma IL-6 (pg/ml) | measured with Luminex assay | measured after challenge with endotoxin at day 7 of medication | No |
Secondary | concentration plasma IL-8 (pg/ml) | measured with Luminex assay | measured after challenge with endotoxin at day 7 of medication | No |
Secondary | concentration plasma IL-10 (pg/ml) | measured with Luminex assay | measured after challenge with endotoxin at day 7 of medication | No |
Secondary | concentration plasma IL-1RA (pg/ml) | measured with Luminex assay | measured after challenge with endotoxin at day 7 of medication | No |
Secondary | concentration plasma IL-1beta (pg/ml) | measured with Luminex assay | measured after challenge with endotoxin at day 7 of medication | No |
Secondary | concentration plasma MCP-1(pg/ml) | measured with Luminex assay | measured after challenge with endotoxin at day 7 of medication | No |
Secondary | concentration plasma MIP-1a(pg/ml) | measured with Luminex assay | measured after challenge with endotoxin at day 7 of medication | No |
Secondary | concentration plasma MIP-1b(pg/ml) | measured after challenge with endotoxin at day 7 of medication | No | |
Secondary | concentration plasma IFNgamma(pg/ml) | measured with Luminex assay | measured after challenge with endotoxin at day 7 of medication | No |
Secondary | plasma adenosine | measured after challenge with endotoxin at day 7 of medication | No | |
Secondary | platelet monocyte complexes | flowcytometric determination of monocytic load with platelets | measured after challenge with endotoxin at day 7 of medication | No |
Secondary | platelet neutrophil complexes | flowcytometric determination of neutrophil load with platelets | measured after challenge with endotoxin at day 7 of medication | No |
Secondary | platelet reactivity | ex vivo stimulation of platelets with ADP and collagen, response measured as P-selectin and fibrinogen) | measured after challenge with endotoxin at day 7 of medication | No |
Secondary | monocytic tissue factor expression | tissue factor expression on monocytes as measured by flow cytometry | measured after challenge with endotoxin at day 7 of medication | No |
Secondary | monocytic HLA-DR expression | as measured by flow cytometry | measured after challenge with endotoxin at day 7 of medication | No |
Secondary | CD14/16 ratio | measured with flow cytometry | measured after challenge with endotoxin at day 7 of medication | No |
Secondary | platelet von Willebrandfactor expression | measured with flow cytometry | measured after challenge with endotoxin at day 7 of medication | No |
Secondary | VASP-P | ELISA | difference between measurement prior to start of study drug after challenge with endotoxin at day 7 of medication | No |
Secondary | symptoms during endotoxin day | 6 point likert scale | measured after challenge with endotoxin at day 7 of medication | No |
Secondary | blood pressure | mmHg | measured after challenge with endotoxin at day 7 of medication | No |
Secondary | temperature | tympanic temperature | measured after challenge with endotoxin at day 7 of medication | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04117802 -
Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome
|
N/A | |
Completed |
NCT02922673 -
The Effects of Acetylsalicylic Acid on Immunoparalysis Following Human Endotoxemia
|
N/A | |
Completed |
NCT01766414 -
In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia - VECTOR II
|
Phase 3 | |
Completed |
NCT04130321 -
Demonstration of the Prebiotic-like Effects of Camu-camu Consumption Against Obesity-related Disorders in Humans
|
N/A | |
Completed |
NCT01474629 -
Probiotic Sport Study
|
N/A | |
Completed |
NCT00246714 -
Pathophysiology and Clinical Relevance of Endotoxin Tolerance in Humans
|
Phase 1 | |
Recruiting |
NCT06147440 -
Different Dietary Patterns
|
N/A | |
Recruiting |
NCT03901807 -
Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study
|
N/A | |
Completed |
NCT03754504 -
Effects of Cranberry Powder Supplements on Gut Microbiota Diversity and Metabolic Syndrome
|
N/A | |
Completed |
NCT03800277 -
Effect of Cranberry and Agaves Extract on Microbiota and Intestinal Health
|
N/A | |
Completed |
NCT00785018 -
In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia
|
N/A | |
Recruiting |
NCT00413348 -
Type 2 Diabetes and the Effect of Probiotics
|
N/A | |
Recruiting |
NCT00413465 -
Study of Renal Blood Flow During Human Endotoxemia
|
N/A | |
Completed |
NCT00412906 -
Study of Gene Activity in Fat and Muscle in Diabetics and Healthy Controls
|
N/A | |
Completed |
NCT05752968 -
Elevated Levels of Antibodies to Endotoxin Core in Hemodialysis Patients With Peripheral Artery Disease
|
||
Completed |
NCT01374711 -
The Effects of Immunostimulation With GM-CSF or IFN-y on Immunoparalysis Following Human Endotoxemia
|
N/A | |
Completed |
NCT00916448 -
The Effects of Atazanavir-induced Hyperbilirubinemia During Human Endotoxemia
|
N/A | |
Completed |
NCT00332267 -
Cerebral Blood Flow and Metabolism During Hypoxia and Endotoxemia
|
N/A | |
Completed |
NCT03482284 -
Effect of Monosaccharides on Intestinal Barrier Function
|
N/A | |
Completed |
NCT03972878 -
Foodprint 1.0: Physiological Acute Responses After Consumption of Confectionary Products
|
N/A |